Atypical haemolytic uraemic syndrome (aHUS) - eculizumab or ravulizumab - continuing authority application form (PB125)

Use this form to apply to continue PBS-subsidised treatment with eculizumab or ravulizumab for aHUS.

Page last updated: 1 January 2024.
QC 21451